Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesions

Rheumatology

Volumn 50, Issue 7, 2011, Pages 1211-1215

  Lombardi, Tommaso ^a   Moll, Solange ^a   Youinou, Pierre ^b   Pers, Jacques Olivier ^b   Tzankov, Alexander ^c   Gabay, Cem ^a,d   Santiago Raber, Marie Laure ^a,c   Chizzolini, Carlo ^d   Huard, Bertrand ^a,d  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

A proliferation inducing ligand; Inflammation; Plasma cells; Sj grens syndrome; TNF

Indexed keywords

APRIL PROTEIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CELL INFILTRATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LEUKOCYTE; MALE; MINOR SALIVA GLAND; MOUTH MUCOSA; NEUTROPHIL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIALOADENITIS; SJOEGREN SIALADENITIS LESION; SJOEGREN SYNDROME; UPREGULATION;

ADULT; AGED; BIOPSY, NEEDLE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMA CELLS; SALIVARY GLANDS, MINOR; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SIALADENITIS; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; UP-REGULATION;

EID: 79959410944     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker016     Document Type: Article

References (26)

1. Hahne M, Kataoka T, Schroter M et al. April, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-90.
2. Shu HB, Hu WH, Johnson H. Tall-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999;65:680-3.
3. Litinskiy MB, Nardelli B, Hilbert DM et al. DCs induce CD40-independent immunoglobulin class switching through BLYS and APRIL. Nat Immunol 2002;3:822-9.
4. Castigli E, Scott S, Dedeoglu F et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004;101:3903-8.
5. He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007;26:812-26.
6. Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2007;109:2961-7.
7. Bossen C, Cachero TG, Tardivel A et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008;111:1004-12.
8. Belnoue E, Pihlgren M, McGaha TL et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111:2755-64.
9. Huard B, McKee T, Bosshard C et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 2008;118:2887-95.
10. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005;8:243-65.
11. Seyler TM, Park YW, Takemura S et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115:3083-92.
12. Gabay C, Krenn V, Bosshard C, Seemayer CA, Chizzolini C, Huard B. Synovial tissues concentrate secreted APRIL. Arthritis Res Ther 2009;11:R144.
13. Chu VT, Enghard P, Schurer S et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009;60: 2083-93.
14. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64.
15. Tak PP, Thurlings RM, Rossier C et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58:61-72.
16. Pena-Rossi C, Nasonov E, Stanislav M et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009;18:547-55.
17. Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum 1993;36:340-7.
18. Schwaller J, Schneider P, Mhawech-Fauceglia P et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007;109:331-8.
19. Burjanadze M, Matthes T, McKee T, Passweg J, Huard B. In situ detection of APRIL-rich niches for plasma-cell survival and their contribution to B-cell lymphoma development. Histol Histopathol 2009;24:1061-6.
20. Schwaller J, Went P, Matthes T et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 2007;21:1324-7.
21. Went P, Tzankov A, Schwaller J, Passweg J, Roosnek E, Huard B. Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases. Exp Hematol 2008;36:533-4.
22. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
23. Salomonsson S, Rozell BL, Heimburger M, Wahren-Herlenius M. Minor salivary gland immunohistology in the diagnosis of primary Sjogren's syndrome. J Oral Pathol Med 2009;38:282-8.
24. Hansen A, Lipsky PE, Dorner T. New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers. Curr Opin Rheumatol 2003;15: 563-70.
25. Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 1984;14:77-105.
26. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197 711-23.